Development and Validation of A UV Spectroscopic Method to Estimate Etoricoxib in Bulk and Tablet Formulation

Stress degradation study of Etoricoxib, isolation, and characterization of major degradation impurity by preparative high‐performance liquid chromatography, liquid chromatography‐mass spectrometry, and nuclear magnetic resonance: Validation of ultra‐performance liquid chromatography method

“…Various analytical methods are available in the literature for the estimation of ETO in formulations and human plasma. Although the forced degradation studies have been described in the literature, [23][24][25][26][27][28][29][30][31][32][33][34], to the best of our knowledge, no reported literature is available on the identification along with their unambiguous structural confirmation of degradation impurities, and analytical method validation along with process-related impurities.…”

“…Various analytical methods are available in the literature for the estimation of ETO in formulations and human plasma. Although the forced degradation studies have been described in the literature, [23–34], to the best of our knowledge, no reported literature is available on the identification along with their unambiguous structural confirmation of degradation impurities, and analytical method validation along with process‐related impurities. In this study, the major degradation impurity namely ETO N‐oxide degradant‐2 (Figure 1: ETO and impurities, 1A) ETO, 1B) N‐oxide degradant‐2, 1C) N‐oxide degradant‐1, 1D) desmethyl ETO, and 1E) ETO sulfoxide) has been isolated, identified and structure confirmed using extensive spectroscopic techniques including 2D NMR and HR‐MS.…”

Untitled

“…Different spectrophotometric methods [6][7][8][9][10] were developed using methanol, 0.1 N HCl, chloroform, etc., for the assay of Etoricoxib. [11] for the quantitative analysis of Etoricoxib in human plasma using acetonitrile:2 mM ammonium acetate (gradient mode), and the linearity was observed as 0.005-5.0 µg/mL.…”